Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury
Mobile Instrumentation for the Detection and Sampling of Aerosol Particles
Emergency Maritime Battery Charger
Swing-Away Winch Cathead Guard
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs
Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring
Handwipe Disclosing Method for Detecting the Presence of Lead
T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use
Summary:
The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research.
Description of Technology:
Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens that are expressed by tumor cells but not by healthy tissues. Current methods to identify such T cells involve extracting autologous antigen presenting cells (APCs) from patients in an expensive, laborious, and time-consuming process.